Clinical Trial

Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 25, 2025 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
About 75% of CNS malignant tumors are classified as gliomas and the IDH-wildtype glioblastoma (GBM) represents the most aggressive form among CNS malignancies. This is a nationwide single-center phase II drug clinical trial with an approximate duration of 32 months. The clinical trial will be single-arm to evaluate the biological activity and effects of metformin in combination with TMZ in patients with GBM.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-06-26; most recent amendment 2025-07-24.
Status change: Not Yet Recruiting → Recruiting 2025-07-24
Trial Details
NCT Number NCT05929495
Lead Sponsor University of Milano Bicocca
Conditions Glioblastoma, IDH-wildtype, Metformin, Malignancies
Enrollment 25 participants
Start Date 2024-02-12
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-25